Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EPS (Weighted Average and Diluted) (2022 - 2025)

Stoke Therapeutics has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.97 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.97 for Q4 2025, down 470.59% from a year ago — trailing twelve months through Dec 2025 was -$0.12 (up 92.81% YoY), and the annual figure for FY2025 was -$0.12, up 92.73%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.97 at Stoke Therapeutics, down from -$0.65 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for STOK hit a ceiling of $1.9 in Q1 2025 and a floor of -$0.97 in Q4 2025.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.58 (2023), compared with a mean of -$0.42.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 433.33% in 2025, while the deepest fall reached 470.59% in 2025.
  • Stoke Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.65 in 2022, then increased by 7.69% to -$0.6 in 2023, then soared by 71.67% to -$0.17 in 2024, then plummeted by 470.59% to -$0.97 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.97 (Q4 2025), -$0.65 (Q3 2025), and -$0.4 (Q2 2025) per Business Quant data.